Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18591772 | 0.89 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3DRD2DRD4 | |
| SCHEMBL30230245 | 0.86 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3DRD2KDM4E | |
| SCHEMBL25839407 | 0.83 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3DRD2KDM4E | |
| SCHEMBL22419324 | 0.78 | POLB (0.43) | DRD2KDM4EGAADRD4HRH3 | |
| SCHEMBL8351022 | 0.76 | HRH3 (0.61) | HRH3 | |
| SCHEMBL4576592 | 0.76 | HRH3 (0.46) | SLC6A2SLC6A4DRD2KDM4EGAA | |
| SCHEMBL8351016 | 0.76 | DRD2 (0.44) | DRD2KDM4EGAADRD4HRH3 | |
| SCHEMBL4576188 | 0.74 | DRD2 (0.49) | DRD2KDM4EGAAHRH3HSD17B10 | |
| SCHEMBL1809859 | 0.74 | KDM4E (0.63) | DRD2KDM4EGAAHSD17B10SIGMAR1 | |
| SCHEMBL8352031 | 0.74 | DRD2 (0.49) | DRD2KDM4EGAAHRH3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | SLC6A2 4559/4885SLC6A4 4578/4885SLC6A3 4535/4885 |
| US-20200155689-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | SLC6A2 4678/4885SLC6A4 4378/4885SLC6A3 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.